B-cells are central components of the adaptive immune response and play a key role in protecting humans from infections. They require programmed DNA lesions, in particular DNA double-strand breaks (DSBs), to become functional.  Unfortunately, these lesions can trigger genomic rearrangements that fuel cancers of B-cell, including lymphoma, leukemia and multiple myeloma.

Our goal is to elucidate how DNA lesions are signalled and repaired in B-cells to allow for a protective immunity but limit B-cell carcinogenesis. Therefore, we are interested in both B-cell biology and the origins of B-cell malignancies. Our mission is to favour the development of better therapies for patients affected by haematological cancers.

We are located in the Lady Davis Institute (LDI), which belongs to Montreal’s Jewish General Hospital. We are affiliated to McGill University, one of the best universities in Canada and around the Globe.

Take a minute to explore our website and get a better idea of what we are doing and our most recent accomplishments.